Cambridge-base EDX Medical launches world’s most advanced testicular cancer test
EDX Medical is launching a non-invasive test for the early detection of testicular cancer.
This test – the world’s most advanced to date – detects cancer recurrences at ultra-high accuracy with 100 per cent sensitivity following treatment and during ongoing surveillance of testicular cancer survivors. It also has exceptional sensitivity in a broad range of men across ethnicities and ages.
Cambridge Science Park-based EDX Medical was founded in 2022 by Professor Sir Christopher Evans, a medical and life sciences entrepreneur with more than 30 years of experience, together with CEO Dr Mike Hudson. The company provides doctors, hospitals and insurers/payers with access to a portfolio of the best clinical diagnostics products and services.
There are around 2,500 new cases of testicular cancer in the UK every year and 50,000 survivors of testicular cancer who could benefit from accurate post-treatment monitoring.
April is Testicular Cancer Awareness Month and greater awareness is being called for by survivors, including former Coronation Street actor Jack James Ryan, radio presenter Chris Stark, and former Welsh international footballer, John Hartson.
The TC100 test involves the taking of a simple blood sample which is sent to EDX Medical for laboratory analysis. The blood sample can be taken easily by a health professional.
Multiple specific tumour biomarkers are analysed and, using a proprietary AI-powered algorithm, a detailed report is prepared for clinicians to help determine the presence or absence of disease and to help guide treatment if required.
More than 30 clinical study reports have confirmed the accuracy and potential clinical usefulness of the test biomarkers, encompassing its use in primary diagnosis, early detection, metastatic disease and recurrence of both seminoma and non-seminoma testicular cancer.
The TC100 test involves the taking of a simple blood sample which is sent to EDX Medical for laboratory analysis. The blood sample can be taken easily by a health professional.
Multiple specific tumour biomarkers are analysed and, using a proprietary AI-powered algorithm, a detailed report is prepared for clinicians to help determine the presence or absence of disease and to help guide treatment, if required.
Jack James Ryan, who campaigns on behalf of the Teenage Cancer Trust, commented: “There’s still such a huge stigma around testicular cancer especially with the process of getting physically checked in the private parts, and that needs to change.
“Being able to give a simple blood sample that is then analysed and that tells you with a high degree of certainty whether you have this cancer or not – as opposed to the physical examinations – would eliminate the awkward and uncomfortable physical process that so many young men shy away from. By making the process of detection easier and more casual – and very accurate – it’ll convince more young men to get tested quicker and in turn will save lives. This really is a game-changer!”
More than 30 clinical study reports have confirmed the accuracy and potential clinical usefulness of the test biomarkers, encompassing its use in primary diagnosis, early detection, metastatic disease, and recurrence of both seminoma and non-seminoma testicular cancer.
Dr Karen Robb, director of programme implementation for cancer at Movember, the leading men’s health charity, said: “During Testicular Cancer Awareness Month, Movember is reminding young men to ‘Know Thy Nuts’ – getting familiar with what’s normal for your body and speaking up if something doesn’t feel right.”
Professor Sir Chris Evans, founder of EDX Medical Group plc, said: “We are delighted to launch in the UK now the best test ever made.
“Given that this disease affects boys from 15 years old to men in their early forties, there are many who could benefit from testing in terms of reassurance, and this particularly applies to people who have been diagnosed and need checked on a regular basis.”
